Advantages of minimally invasive surgery for remnant gastric cancer: A multi-institutional cohort study.

Authors

null

Ryuhei Aoyama

Department of Surgery, Kyoto University, Kyoto, Japan;

Ryuhei Aoyama , Shigeru Tsunoda , Ryosuke Okamura , Yoshito Yamashita , Hiroaki Hata , Yousuke Kinjo , Akira Miki , Seiichiro Kanaya , Michihiro Yamamoto , Koichi Matsuo , Dai Manaka , Atsushi Itami , Takatsugu Kan , Tetsuo Ito , Kenjiro Hirai , Hisahiro Hosogi , Tatsuto Nishigori , Shigeo Hisamori , Nobuaki Hoshino , Kazutaka Obama

Organizations

Department of Surgery, Kyoto University, Kyoto, Japan; , Department of Surgery, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan; , Department of Surgery, National Hospital Organization Kyoto Medical Center, Kyoto, Japan; , Department of Gastroenterological Surgery and Oncology, Himeji Medical Center, Himeji, Japan; , Department of Surgery, Toyooka Hospital, Toyooka, Japan; , Osaka Red Cross Hospital, Osaka, Japan; , Department of Surgery, Shiga General Hospital, Moriyama, Japan; , Department of Surgery, Kyoto City Hospital, Kyoto, Japan; , Department of Surgery, Kyoto Katsura Hospital, Kyoto, Japan; , Department of Surgery, Kobe City Nishi-Kobe Medical Center, Kobe, Japan; , Department of Surgery, Kobe City Medical Center West Hospital, Kobe, Japan; , Gastroenterological Surgery, Osaka Saiseikai-Noe Hospital, Osaka, Japan; , Department of Surgery, Otsu City Hospital, Otsu, Japan; , Osaka Red-Cross Hospital, Osaka, Japan;

Research Funding

No funding received
None.

Background: Remnant gastric cancer (RGC) is defined as a cancer arising in the remnant stomach after initial gastrectomy, regardless of the previous disease or surgical procedure. Despite growing evidence of the effectiveness of minimally invasive surgery (MIS) for primary gastric cancer, MIS for RGC remains controversial due to the rarity of the disease. This study aimed to evaluate the surgical and oncological outcomes of MIS for radical resection of RGC. Methods: We collected the data of patients with RGC who underwent surgery with curative intent between 2005 and 2020 from 17 institutions in Japan, and performed a propensity score (PS) matching analysis to compare the short- and long-term outcomes of MIS with open surgery. Results: A total of 327 patients were included in this study and 186 patients were analyzed after matching. The risk ratios for overall and severe complications were 0.76 (95% confidence interval [CI]: 0.45–1.27) and 0.65 (95% CI: 0.32–1.29), respectively. The MIS group had significantly less blood loss (50 ml vs. 361 ml, P<0.001) and a shorter hospital stay (13 days vs. 16 days, P=0.009) than the open surgery group, while the operative time was longer in the MIS group (344 min vs. 273 min, P<0.001). The median follow-up duration of this cohort was 4.6 years, and the 3-year overall survival rates were 77.9% in the MIS group and 76.2% in the open surgery group (hazard ratio [HR], 0.78; 95% CI: 0.45–1.36). The 3-year relapse-free survival rates were 71.9% in the MIS group and 62.2% in the open surgery group (HR, 0.71; 95% CI: 0.44–1.16). Locoregional recurrence occurred in three patients (3.2%) in the MIS group and four patients (4.3%) in the open surgery group. There were also no differences in the other patterns of recurrence between the groups. Conclusions: MIS for RGC showed favorable short- and long-term outcomes compared to open surgery. MIS is a promising option for radical surgery for RGC.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 357)

DOI

10.1200/JCO.2023.41.4_suppl.357

Abstract #

357

Poster Bd #

E18

Abstract Disclosures